US2002137023A1PendingUtilityA1

Methods and compositions for targeting compounds to muscle

50
Assignee: UNIV AUBURNPriority: May 29, 1997Filed: Sep 5, 2001Published: Sep 26, 2002
Est. expiryMay 29, 2017(expired)· nominal 20-yr term from priority
Inventors:Bruce F. SmithTatiana Samoilova
A61K 38/00A61K 48/00G01N 2800/2878G01N 33/6887A61K 47/62C07K 14/4708C12N 15/87C07K 7/06C07K 14/4716G01N 2800/2885
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions for use in targeting therapies to muscle cells are provided. The compositions comprise peptides which are capable of binding muscle cells in vivo.

Claims

exact text as granted — not AI-modified
That which is claimed:  
     
         1 . A method for determining muscle-type specific peptides, said method comprising constructing a bacteriophage library which expresses random peptides at the amino terminus of a phage protein, and hybridizing the resulting phage to muscle cells of interest wherein said peptides are selected based on in vivo binding.  
     
     
         2 . The method of  claim 1 , wherein said peptides are random peptides.  
     
     
         3 . The method of  claim 1 , wherein said peptides are 7-mer peptides.  
     
     
         4 . The method of  claim 1 , wherein said muscle-type specific peptides are species specific.  
     
     
         5 . The peptides of  claim 1 , wherein said muscle-type specific peptides are species independent.  
     
     
         6 . The method of  claim 1 , wherein said muscle-type specific peptides are capable of binding to specific muscle cells selected from the group consisting of smooth, skeletal and cardiac muscle cells.  
     
     
         7 . The method of  claim 6 , wherein said muscle cells are skeletal muscle cells.  
     
     
         8 . The method of  claim 6 , wherein said muscle cells are cardiac muscle cells.  
     
     
         9 . The method of  claim 1 , wherein said muscle-type specific peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28.  
     
     
         10 . A method for targeting a pharmaceutical composition to muscle cells, said method comprising ligating a muscle-type specific peptide to said pharmaceutical composition.  
     
     
         11 . The method of  claim 10 , wherein said pharmaceutical composition is selected from drugs, proteins, and nucleic acids.  
     
     
         12 . The method of  claim 10 , wherein said pharmaceutical composition is useful for treating a myopathy.  
     
     
         13 . The method of  claim 10 , wherein said peptides are random peptides.  
     
     
         14 . The method of  claim 10 , wherein said peptides are 7-mer peptides.  
     
     
         15 . The method of  claim 10 , wherein said muscle-type specific peptides are species specific.  
     
     
         16 . The peptides of  claim 10 , wherein said muscle-type specific peptides are species independent.  
     
     
         17 . The method of  claim 10 , wherein said muscle-type specific peptides are capable of binding to specific muscle cells selected from the group consisting of smooth, skeletal and cardiac muscle cells.  
     
     
         18 . The method of  claim 17 , wherein said muscle cells are skeletal muscle cells.  
     
     
         19 . The method of  claim 17 , wherein said muscle cells are cardiac muscle cells.  
     
     
         20 . The method of  claim 10 , wherein said muscle-type specific peptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28.  
     
     
         21 . A nucleotide sequence encoding the peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29.  
     
     
         22 . A method for treating a patient having a muscular disorder, said method comprising administering to said patient a pharmaceutically-effective amount of a composition comprising a muscle-type specific peptide operably linked to a pharmaceutical composition useful for treating said disorder.  
     
     
         23 . The method of  claim 22 , wherein said peptide is species specific.  
     
     
         24 . The method of  claim 22 , wherein said peptide is species independent.  
     
     
         25 . The method of  claim 22 , wherein said peptide is capable of binding specific muscle cells selected from the group consisting of cardiac, skeletal, and smooth muscle cells.  
     
     
         26 . The method of  claim 22 , wherein said muscle-type specific peptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28.

Join the waitlist — get patent alerts

Track US2002137023A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.